CYPS: AI 评分 53/100 — AI 分析 (4月 2026)

Cyclo3pss Corporation, founded in 1927, focuses on ozone-based food processing and laundry systems. The company suspended operations in 2002 due to financing difficulties but remains listed on the OTC market.

Key Facts: AI Score: 53/100 Sector: Healthcare

公司概况

概要：

Cyclo3pss Corporation, an OTC-listed entity in the healthcare sector, specializes in ozone technology for food processing and laundry systems. Despite suspending operations in 2002 due to financial constraints, the company maintains its focus on sterilization and disinfection technologies, operating with a negative profit margin and high beta.

CYPS是做什么的？

Cyclo3pss Corporation, established in 1927 and based in Salt Lake City, Utah, is a company focused on the development, manufacture, and sale of ozone-based technologies. Initially, the company's core business revolved around ozone food processing products designed to enhance food safety and extend shelf life. Additionally, Cyclo3pss offered ozone washing and laundry sorting systems tailored for commercial and institutional laundries, aiming to improve efficiency and hygiene in these settings. The company also engaged in research and development efforts aimed at creating sterilization and disinfection technologies for consumer products. However, in July 2002, Cyclo3pss faced significant financial challenges, leading its Board of Directors to suspend all operations. This decision stemmed from the company's inability to secure necessary financing and attract willing investors to support its ongoing activities. Despite this operational suspension, Cyclo3pss remains a publicly listed entity, trading on the OTC market. The company's historical focus on ozone technology positions it within the broader landscape of sterilization and disinfection solutions, though its current operational status limits its active participation in the market.

CYPS的投资论点是什么？

Cyclo3pss Corporation presents a speculative investment opportunity due to its current operational suspension and OTC listing. The company's historical focus on ozone technology for food processing and laundry systems could represent potential value if operations were to resume. However, the negative profit margin of -232.3% and negative free cash flow indicate severe financial distress. The extremely high beta of 41.00 suggests very high volatility relative to the market. Any investment would depend on the potential for a turnaround, new financing, or strategic acquisition, all of which are highly uncertain. Investors should carefully consider the risks associated with OTC-listed companies and the lack of current operations.

CYPS在哪个行业运营？

Cyclo3pss Corporation operates within the diagnostics and research segment of the healthcare sector. This segment is characterized by innovation in sterilization and disinfection technologies. The market for ozone-based sterilization systems is competitive, with companies like CVHIF, EMGE, KLDO, NMRD, and NMXS offering alternative solutions. Given Cyclo3pss's operational suspension since 2002, it currently holds a marginal position in the industry, pending any potential resumption of operations or strategic repositioning.

Diagnostics & Research

Healthcare

CYPS有哪些增长机遇？

Resumption of Operations: If Cyclo3pss were to secure new financing and resume operations, it could capitalize on the growing demand for advanced sterilization technologies in the food processing and healthcare industries. The market for food safety technologies is projected to reach billions of dollars, offering a substantial opportunity for growth if the company can regain its operational footing. Timeline: 2-5 years.
Strategic Acquisition: Cyclo3pss's intellectual property and historical presence in the ozone technology sector could make it an attractive acquisition target for a larger company seeking to expand its portfolio. An acquisition could provide the necessary capital and resources to revitalize the company's operations and leverage its existing assets. Timeline: 1-3 years.
Partnerships and Licensing: Cyclo3pss could explore partnerships and licensing agreements with other companies in the healthcare or food processing industries to generate revenue from its existing technologies. This approach would allow the company to leverage its intellectual property without the need for significant capital investment. Timeline: 1-2 years.
Expansion into New Markets: The company could explore opportunities to expand its ozone technology into new markets, such as water treatment or air purification. These markets are experiencing growth due to increasing concerns about environmental sustainability and public health, offering potential avenues for diversification. Timeline: 3-5 years.
Development of New Products: Cyclo3pss could invest in research and development to create new ozone-based products and solutions that address emerging needs in the sterilization and disinfection market. This could involve developing more efficient and cost-effective ozone generators or exploring new applications for ozone technology in healthcare settings. Timeline: 3-5 years.

Market capitalization of $0.00B indicates a micro-cap or nano-cap valuation, reflecting the company's small size and limited operations.
Negative profit margin of -232.3% highlights significant financial losses and operational inefficiencies.
Gross margin of 36.6% suggests some ability to generate profit from sales, but this is overshadowed by high operating expenses.
Negative free cash flow (FCF) indicates the company is not generating sufficient cash from its operations to cover its expenses and investments.
Beta of 41.00 indicates extremely high volatility compared to the market, implying a high-risk investment.

CYPS提供哪些产品和服务？

Licenses ozone food processing products.
Manufactures ozone food processing products.
Sells ozone food processing products.
Installs ozone food processing products.
Licenses ozone washing systems for commercial laundries.
Manufactures ozone washing systems for commercial laundries.
Sells ozone washing systems for commercial laundries.
Engages in R&D of sterilization and disinfection technologies.

CYPS如何赚钱？

Licensing of ozone technology to other businesses.
Direct sales of ozone-based products and systems.
Installation and maintenance services for ozone systems.
Research and development of new ozone-based applications.

Food processing companies seeking to improve food safety.
Commercial and institutional laundries aiming to enhance efficiency and hygiene.
Potential partners in the healthcare and environmental sectors.
Consumers seeking sterilization and disinfection solutions (future potential).

Proprietary ozone technology (if patents are still valid).
Established presence in the ozone technology market (historical).
Potential for intellectual property licensing.
First-mover advantage in specific niche markets (historical).

什么因素可能推动CYPS股价上涨？

Upcoming: Potential acquisition offer from a larger healthcare company.
Upcoming: Securing new financing to resume operations.
Ongoing: Research and development efforts to create new ozone-based products.
Ongoing: Pursuit of strategic partnerships and licensing agreements.

CYPS的主要风险是什么？

Potential: Continued inability to secure financing and resume operations.
Potential: Technological obsolescence of ozone technology.
Ongoing: Intense competition from established players in the sterilization market.
Ongoing: Limited liquidity and high volatility due to OTC listing.
Ongoing: Risk of delisting from the OTC market.

CYPS的核心优势是什么？

Historical expertise in ozone technology.
Potential intellectual property assets.
Established brand name (historical).
Potential for strategic partnerships.

CYPS的劣势是什么？

Suspended operations since 2002.
Lack of current revenue generation.
Negative profit margin and free cash flow.
Limited financial resources.

CYPS有哪些机遇？

Resumption of operations with new financing.
Strategic acquisition by a larger company.
Licensing of ozone technology to other businesses.
Expansion into new markets and applications.

CYPS面临哪些威胁？

Competition from established players in the sterilization market.
Technological obsolescence.
Regulatory changes affecting ozone technology.
Continued inability to secure financing.

CYPS的竞争对手是谁？

CV Holdings, Inc. — Operates in diverse sectors, including healthcare investments. — (CVHIF)
Emge Corp. — Unknown business focus based on available data. — (EMGE)
Kaleido Biosciences, Inc. — Focuses on microbiome metabolic therapies. — (KLDO)
Nemaura Medical, Inc. — Develops non-invasive wearable diagnostic devices. — (NMRD)
NEMUS Bioscience, Inc. — Develops cannabinoid-based therapeutics. — (NMXS)

Key Metrics

MoonshotScore: 53/100

Company Profile

Headquarters: Salt Lake City, United States
Employees: 4

AI Insight

AI analysis pending for CYPS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cyclo3pss Corporation do?

Cyclo3pss Corporation historically focused on developing, manufacturing, and selling ozone-based products for food processing and commercial laundry applications. The company aimed to improve food safety and hygiene through its ozone technology. However, Cyclo3pss suspended its operations in 2002 due to financial constraints and has not resumed them since. Currently, the company's activities are limited, and its future prospects depend on securing new financing or a strategic acquisition.

What are the key growth opportunities for CYPS in healthcare?

Given Cyclo3pss's suspended operations, immediate growth opportunities in healthcare are limited. However, potential opportunities could arise from a resurgence in demand for ozone-based sterilization technologies, particularly in niche applications where ozone offers a competitive advantage. The company could also explore licensing its intellectual property to other healthcare companies or partnering on research and development projects. Any growth would depend on securing funding and adapting its technology to current market needs.

What are the main risks for CYPS?

The primary risk for Cyclo3pss is its continued operational suspension and the uncertainty surrounding its future. The company faces the risk of technological obsolescence, as newer sterilization technologies may emerge. Additionally, Cyclo3pss faces competition from established players in the sterilization market, and its limited financial resources make it difficult to compete effectively. The OTC listing also carries risks related to liquidity, volatility, and regulatory oversight.

What revenue streams does Cyclo3pss Corporation have in healthcare?

Currently, Cyclo3pss Corporation does not have any active revenue streams in healthcare due to its suspended operations since 2002. Historically, potential revenue streams could have included sales of ozone-based sterilization equipment to hospitals and healthcare facilities, licensing of its ozone technology for use in medical devices, and providing maintenance and support services for its installed equipment. However, these revenue streams are currently non-existent.

What do analysts say about CYPS stock?

Due to Cyclo3pss Corporation's OTC listing and suspended operations, there is limited to no analyst coverage available. Key valuation metrics such as price-to-earnings ratio and price-to-sales ratio are not meaningful in the absence of revenue and earnings. Any investment in CYPS would be highly speculative and based on the potential for a turnaround rather than traditional financial analysis. Investors should conduct thorough due diligence and carefully consider the risks before investing.